KCNAB2 Antibody

What is KCNAB2 and why is it significant in biomedical research?

KCNAB2 (potassium voltage-gated channel subfamily A regulatory beta subunit 2) is a regulatory protein that modifies the properties of functional potassium voltage-gated alpha subunits. In humans, the canonical protein consists of 367 amino acid residues with a molecular mass of 41 kDa. KCNAB2 has subcellular localization in both the cell membrane and cytoplasm, with up to five different isoforms reported .

The protein is notably expressed in myelinated nerve fibers in the spinal cord, in the juxtaparanodal region of the nodes of Ranvier, and in the paranodal region. It belongs to the Shaker potassium channel beta subunit protein family and also encodes an aldo-keto reductase that negatively regulates members of the voltage-gated potassium channel family .

Recent research has revealed KCNAB2's significance in cancer biology. The gene has been found to be downregulated in non-small-cell lung cancer (NSCLC) and lung adenocarcinoma (LUAD), where it appears to function as a tumor suppressor and modulator of immune cell infiltration .

What are the common applications of KCNAB2 antibodies in laboratory research?

KCNAB2 antibodies are employed in multiple immunodetection techniques to study the expression, localization, and function of this important regulatory protein:

• Western Blot: The most widely used application for detecting and quantifying KCNAB2 protein levels in cell and tissue lysates

• Immunohistochemistry (IHC): Commonly used to visualize KCNAB2 expression patterns in tissue sections

• Immunofluorescence (IF): Utilized to determine subcellular localization of KCNAB2 in cells and tissues

• Flow Cytometry: For quantitative analysis of KCNAB2 expression in cell populations

• Immunoprecipitation: To isolate KCNAB2 and its binding partners for interaction studies

These methods provide complementary approaches to investigate KCNAB2's expression patterns in normal versus diseased states, particularly in cancer research where KCNAB2 has emerged as a potential biomarker and therapeutic target .

What types of KCNAB2 antibodies are available for research purposes?

Researchers have access to several types of KCNAB2 antibodies, each with distinct characteristics:

Commercial suppliers offer KCNAB2 antibodies with reactivity against human, mouse, rat, and other species, with unconjugated options being most common . Recombinant monoclonal antibodies, such as the mouse anti-KCNAB2 K17/70R antibody, represent a newer generation of highly specific and reproducible reagents for KCNAB2 research .

How should researchers validate KCNAB2 antibodies for experimental use?

Proper validation of KCNAB2 antibodies is critical for obtaining reliable and reproducible results. A comprehensive validation strategy should include:

• Positive and negative controls:

  • Use tissues or cell lines with known high expression (spinal cord, brain) versus low expression

  • Include KCNAB2 knockout/knockdown samples as negative controls

• Multi-technique validation:

  • Confirm specificity across Western blot, IHC, and IF applications

  • Verify expected molecular weight (~41 kDa for canonical isoform) in Western blot

  • Observe expected subcellular localization (membrane and cytoplasmic) in IF

• Cross-antibody validation:

  • Compare results from antibodies targeting different epitopes

  • Use both monoclonal and polyclonal antibodies when possible

• Functional validation:

  • Confirm that antibody can detect changes in KCNAB2 expression following experimental manipulation

  • Test ability to immunoprecipitate KCNAB2 and its known binding partners

This systematic approach ensures the antibody's specificity and sensitivity before proceeding with experimental applications, particularly in complex tissues or disease models .

What are optimal protocols for detecting KCNAB2 in lung cancer tissue samples?

For detecting KCNAB2 in lung cancer tissues, researchers should consider these methodological approaches:

Immunohistochemistry Protocol:

• Fixation: 10% neutral buffered formalin (24-48 hours)

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Blocking: 5% normal serum in PBS (1 hour, room temperature)

• Primary antibody: Dilute KCNAB2 antibody 1:100-1:500 in blocking buffer (overnight, 4°C)

• Secondary antibody: HRP-conjugated appropriate secondary (1 hour, room temperature)

• Detection: DAB chromogen

• Counterstain: Hematoxylin

• Evaluation: Score staining intensity (0-3+) and percentage of positive cells

Immunofluorescence Protocol:

• Section preparation: 5-7 μm FFPE or frozen sections

• Permeabilization: 0.1% Triton X-100 in PBS (10 minutes)

• Blocking: 5% BSA in PBS (1 hour)

• Primary antibody: Anti-KCNAB2 (1:100) with co-staining markers (overnight, 4°C)

• Secondary antibody: Fluorophore-conjugated (1:500, 1 hour, room temperature)

• Counterstain: DAPI for nuclei

• Mounting: Anti-fade medium

These protocols have been utilized in studies examining KCNAB2's downregulation in lung adenocarcinoma and non-small-cell lung cancer, where its expression correlates with prognosis and immune infiltration .

How can researchers effectively employ KCNAB2 antibodies in cancer cell line studies?

When studying KCNAB2 in cancer cell lines, researchers should implement these methodological approaches:

Western Blot Analysis:

• Lysate preparation: Use RIPA buffer with protease inhibitors

• Protein loading: 20-50 μg total protein per lane

• Separation: 10-12% SDS-PAGE

• Transfer: PVDF membrane, wet transfer (100V, 90 minutes)

• Blocking: 5% non-fat milk in TBST (1 hour)

• Primary antibody: Anti-KCNAB2 (1:1000 in blocking solution, overnight at 4°C)

• Secondary antibody: HRP-conjugated (1:5000, 1 hour)

• Detection: Enhanced chemiluminescence

• Analysis: Normalize to loading controls (β-actin, GAPDH)

Functional Studies:

• Overexpression: Transfect cells with KCNAB2 expression vectors to assess effects on proliferation, migration, and apoptosis

• Knockdown/knockout: Use siRNA or CRISPR/Cas9 to reduce KCNAB2 expression

• Phenotypic assays: Measure cell growth, motility, invasion, and apoptosis

• Signaling pathway analysis: Assess effects on AKT-mTOR signaling via Western blot

These approaches have demonstrated that KCNAB2 overexpression suppresses growth, proliferation, and motility of NSCLC cells while promoting apoptosis, whereas KCNAB2 knockout promotes malignant behaviors .

How can KCNAB2 antibodies be utilized to investigate its role in immune cell infiltration?

KCNAB2's emerging role in immune cell infiltration can be studied using several sophisticated approaches:

• Multiplex immunohistochemistry:

  • Co-stain tissues with KCNAB2 antibodies and immune cell markers (CD3, CD4, CD8, CD68)

  • Analyze spatial relationships between KCNAB2 expression and immune infiltrates

  • Quantify using digital pathology software

• Chemokine expression analysis:

  • Following KCNAB2 overexpression in cell lines, collect conditioned media

  • Perform ELISA or multiplex cytokine arrays to measure secreted chemokines

  • Validate changes in CCL2, CCL3, CCL4, CCL18, CXCL9, CXCL10, and CXCL12 levels

• Immune cell migration assays:

  • Use conditioned media from KCNAB2-modified cells in transwell migration assays

  • Track migration of different immune cell populations

  • Correlate with KCNAB2 expression levels

• Single-sample Gene Set Enrichment Analysis (ssGSEA):

  • Assess relative enrichment of 24 immune cell types in relation to KCNAB2 expression

  • Use Spearman's correlation to examine relationships between KCNAB2 and immune cells

These methods leverage KCNAB2 antibodies to understand how this protein influences immune infiltration, potentially affecting immunotherapy responses in cancer patients .

What approaches can resolve contradictory findings on KCNAB2 expression across different tumor types?

Resolving contradictory findings regarding KCNAB2 expression requires systematic analytical approaches:

• Context-specific analysis:

  • Compare KCNAB2 expression across cancer types using antibody-based tissue microarrays

  • Stratify by histological subtype, grade, and stage

  • Correlate with genetic background (mutation profiles, CNVs)

• Isoform-specific detection:

  • Use antibodies targeting different KCNAB2 isoforms

  • Perform RT-PCR with isoform-specific primers alongside protein detection

  • Document which isoforms predominate in different cancer types

• Subcellular localization studies:

  • Perform subcellular fractionation followed by Western blot

  • Use confocal microscopy with KCNAB2 antibodies to track localization

  • Determine if function varies with localization across cancer types

• Integrative bioinformatic analysis:

  • Compare antibody-based findings with mRNA expression data

  • Analyze TCGA and GEO datasets stratified by cancer type

  • Create comprehensive expression maps across cancer types and stages

Studies have shown significant downregulation of KCNAB2 in lung adenocarcinoma, correlating with poor prognosis, but its expression and role may differ in other cancers, necessitating careful comparative studies .

How can researchers use KCNAB2 antibodies to explore its interaction with the AKT-mTOR pathway?

The relationship between KCNAB2 and the AKT-mTOR pathway can be investigated using these advanced methods:

• Proximity ligation assay (PLA):

  • Use KCNAB2 antibodies alongside antibodies against AKT, mTOR components

  • Visualize protein-protein interactions in situ

  • Quantify interaction signals in different cellular compartments

• Co-immunoprecipitation:

  • Immunoprecipitate KCNAB2 using specific antibodies

  • Blot for AKT, mTOR pathway components

  • Perform reverse IP to confirm interactions

• Phosphorylation status analysis:

  • Following KCNAB2 overexpression or knockout

  • Western blot with phospho-specific antibodies for AKT, mTOR, S6K, 4EBP1

  • Quantify changes in pathway activation

• Protein array analysis:

  • Use KCNAB2-overexpressed cells to identify downstream effects

  • Analyze phosphorylation changes in AKT-mTOR pathway components

  • Validate findings with targeted Western blots

These approaches have revealed that KCNAB2 overexpression inhibits AKT-mTOR signaling activation in NSCLC cells, while KCNAB2 knockout augments this pathway, suggesting a potential mechanism for its tumor-suppressive effects .

How should researchers address non-specific binding or background issues with KCNAB2 antibodies?

Non-specific binding and background issues can be addressed through methodical optimization:

• Antibody titration:

  • Test serial dilutions (1:100 to 1:5000) to determine optimal concentration

  • Balance specific signal against background

  • Create titration curves for each application

• Blocking optimization:

  • Compare different blocking agents (BSA, normal serum, commercial blockers)

  • Increase blocking time (1-2 hours at room temperature)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

• Washing protocols:

  • Increase wash times and number of washes

  • Use higher salt concentration in wash buffers (150-500 mM NaCl)

  • Add 0.05-0.1% Tween-20 to improve stringency

• Alternative detection systems:

  • Try polymer-based detection systems for IHC

  • Use tyramide signal amplification for weak signals while maintaining specificity

  • Consider fluorescent secondary antibodies with lower background

• Antibody validation controls:

  • Include peptide competition assays to confirm specificity

  • Use KCNAB2 knockout/knockdown samples as negative controls

  • Compare multiple antibodies targeting different epitopes

These approaches ensure reliable and specific detection of KCNAB2 across different experimental systems, particularly important when examining tissues with varying expression levels .

What factors should be considered when interpreting KCNAB2 expression data in relation to patient outcomes?

When correlating KCNAB2 expression with clinical outcomes, researchers should consider these analytical factors:

How can researchers reconcile in vitro KCNAB2 functional studies with clinical observations?

Bridging in vitro findings with clinical observations requires systematic approaches:

• Clinically relevant models:

  • Use patient-derived xenografts or organoids that maintain tumor heterogeneity

  • Compare multiple cell lines representing different disease subtypes

  • Consider 3D culture systems that better recapitulate in vivo conditions

• Validation in multiple systems:

  • Confirm in vitro findings in animal models

  • Use multiple experimental approaches (overexpression, knockdown)

  • Test effects across cell lines with different genetic backgrounds

• Translational validation:

  • Correlate in vitro phenotypes with patient tissue analysis

  • Perform IHC on tissue microarrays to validate expression patterns

  • Match molecular mechanisms identified in vitro with pathway activation in patient samples

• Clinical correlation analysis:

  • Design retrospective studies examining KCNAB2 expression in patient cohorts

  • Correlate with treatment response and survival outcomes

  • Consider multivariate analysis accounting for known prognostic factors

This integrated approach has successfully demonstrated that KCNAB2's tumor-suppressive effects observed in vitro (inhibition of proliferation, promotion of apoptosis) correspond with better clinical outcomes in patients with higher KCNAB2 expression, validating its biological significance .

How might KCNAB2 antibodies contribute to developing new cancer immunotherapy approaches?

KCNAB2 antibodies could advance cancer immunotherapy research through several innovative approaches:

• Biomarker development:

  • Use KCNAB2 antibodies to stratify patients for immunotherapy trials

  • Correlate KCNAB2 expression with immune checkpoint marker expression

  • Develop multiplex IHC panels including KCNAB2 and immune markers

• Mechanism elucidation:

  • Investigate how KCNAB2 modulates chemokine production

  • Map signaling pathways connecting KCNAB2 to immune cell recruitment

  • Identify targetable nodes in KCNAB2-mediated immune regulation

• Therapeutic design:

  • Develop approaches to upregulate KCNAB2 expression in tumors

  • Screen for compounds that mimic KCNAB2's effects on chemokine expression

  • Create combination strategies targeting both KCNAB2 pathways and immune checkpoints

• Response monitoring:

  • Track changes in KCNAB2 expression during immunotherapy

  • Correlate with changes in immune infiltration and clinical response

  • Develop resistance biomarker panels including KCNAB2

Research has established that KCNAB2 influences immune cell infiltration through modulation of chemokine expression (CCL2, CCL3, CCL4, CCL18, CXCL9, CXCL10, and CXCL12), suggesting its potential as a biomarker for immunotherapy response and a target for enhancing immune infiltration in tumors .

What novel technological approaches are advancing KCNAB2 research beyond traditional antibody applications?

Cutting-edge technologies are expanding KCNAB2 research beyond conventional antibody applications:

• Mass spectrometry-based proteomics:

  • Quantify KCNAB2 protein without antibody limitations

  • Identify post-translational modifications

  • Map KCNAB2 interaction networks comprehensively

• CRISPR-based genomic screens:

  • Identify synthetic lethal interactions with KCNAB2

  • Discover genes that modulate KCNAB2 expression

  • Engineer cell lines with tagged endogenous KCNAB2 for live imaging

• Single-cell technologies:

  • Combine KCNAB2 antibodies with single-cell RNA-seq

  • Correlate protein levels with transcriptional states

  • Map expression across heterogeneous tumor microenvironments

• Spatial transcriptomics/proteomics:

  • Visualize KCNAB2 expression in spatial context

  • Correlate with immune cell localization

  • Develop better understanding of KCNAB2 in tissue architecture

• Drug discovery platforms:

  • Screen for compounds that modulate KCNAB2 expression or function

  • Develop targeted protein degradation approaches for KCNAB2 interactors

  • Identify pathway-specific inhibitors based on KCNAB2 mechanisms

These technological advances are helping researchers better understand KCNAB2's role in cancer biology and immune regulation, potentially leading to novel therapeutic strategies .

How can researchers leverage KCNAB2 expression data to develop precision medicine approaches for lung cancer?

KCNAB2-based precision medicine strategies for lung cancer could include:

• Prognostic stratification:

  • Develop KCNAB2 IHC scoring systems standardized across laboratories

  • Create multivariate prognostic models incorporating KCNAB2 expression

  • Identify patient subgroups with differential recurrence risks based on KCNAB2 status

• Predictive biomarker development:

  • Correlate KCNAB2 expression with response to conventional treatments

  • Determine if KCNAB2 status predicts immunotherapy efficacy

  • Identify combination approaches most effective for KCNAB2-low tumors

• Therapeutic targeting strategies:

  • Screen for drugs that restore KCNAB2 expression in lung cancer

  • Identify synthetic lethal interactions in KCNAB2-low tumors

  • Develop targeted approaches to compensate for KCNAB2 loss

• Clinical trial design:

  • Incorporate KCNAB2 testing in patient selection criteria

  • Design trials specifically targeting patients with low KCNAB2 expression

  • Include KCNAB2 monitoring as a pharmacodynamic marker

Research has established that KCNAB2 downregulation correlates with poor prognosis across multiple lung cancer patient subgroups, suggesting its potential as a clinically relevant biomarker. Its connection to AKT-mTOR signaling and immune infiltration provides mechanistic rationale for precision medicine approaches targeting these pathways in KCNAB2-low tumors .